38 results
8-K
EX-99.1
DRRX
Durect Corp
8 May 23
DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update
4:15pm
p.m. ET in New York City. The event will include presentations by Dr. Paul Gaglio and Dr. Brett Fortune, as well as members of our senior leadership
8-K
EX-99.1
DRRX
Durect Corp
5 Jul 22
DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer
9:01am
are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT
8-K
EX-99.1
lnm90i 1lfqq
14 Dec 21
DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia
9:16am
8-K
dwq1g5a440h du
5 Jan 21
DURECT Corporation Appoints Two New Board Members
9:00am
8-K
EX-99.1
tqynmkl ay8vae
5 Jan 21
DURECT Corporation Appoints Two New Board Members
9:00am
8-K
EX-99.1
kq40fjp26m
2 Nov 20
DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer
4:16pm
8-K
5ef9eesihnu
2 Nov 20
DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer
4:16pm
8-K
EX-99.1
o190uli946cl2pfjjok
23 Jul 19
DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
2:08pm
8-K
EX-99.1
o0nasna4 9q4702j4ts
27 Jun 19
DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter
12:45pm
8-K
EX-99.1
5e6s6en rmszvc9
27 Feb 19
DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter
9:00am